bupropion sustained-release / Generic mfg. - LARVOL DELTA

Comparative Risk of New-Onset Seizure Among Smoking Cessation Pharmacotherapies (AES 2025) - "A p-value of < 0.05 was considered significant. Nicotine replacement therapy (NRT) (1,417; 27%), varenicline (3,153; 62%), bupropion sustained-release (244; 5%), or combination therapy (328; 6%) were used. This study demonstrates that overall incidence of new-onset seizures is high in tobacco smokers started on SCT. When comparing treatment groups, increased risk of new-onset seizure was identified only with NRT relative to varenicline. Although smoking cessation has significant health benefits, patients on SCT require close monitoring for seizure occurrence."

CNS Disorders • Epilepsy • Tobacco Cessation

Restoring STAR*D: A RIAT Reanalysis of Medication Augmentation Therapy After Failed SSRI Treatment Using Patient-Level Data with Fidelity to the Original Research Protocol. (PubMed, medRxiv) - "A similar reanalysis is warranted for STAR*D's augmentation study in which citalopram was augmented with sustained-release bupropion or buspirone. Compared with the original STAR*D publication, our reanalysis identified inflated remission rates, low sustained remission, and marked differences in TESI risk between augmentation strategies. These findings suggest that both treatments offer lower acute and sustained benefit than is widely understood, with buspirone associated with more TESI."

Journal • Psychiatry • Suicidal Ideation

CPT-SMART for Treatment of PTSD and Cigarette Smoking (clinicaltrials.gov) - P4 | N=120 | Completed | Sponsor: VA Office of Research and Development | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

CPT-SMART for Treatment of PTSD and Cigarette Smoking (clinicaltrials.gov) - P4 | N=120 | Active, not recruiting | Sponsor: VA Office of Research and Development | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness (clinicaltrials.gov) - P4 | N=131 | Completed | Sponsor: University of California, San Francisco | Recruiting ➔ Completed

Trial completion • CNS Disorders • Nicotine Addiction • Tobacco Addiction • Tobacco Cessation

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening (clinicaltrials.gov) - P=N/A | N=3228 | Completed | Sponsor: Abramson Cancer Center at Penn Medicine | Active, not recruiting ➔ Completed

Trial completion • Lung Cancer • Oncology • Solid Tumor • Tobacco Cessation

Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya (clinicaltrials.gov) - P4 | N=580 | Completed | Sponsor: University of California, San Francisco | Active, not recruiting ➔ Completed | Trial completion date: Sep 2025 ➔ Jan 2025

Trial completion • Trial completion date • Human Immunodeficiency Virus • Infectious Disease • Tobacco Cessation

Tirzepatide Affect Sexual Function in Women: Case Report. (PubMed, Clin Med Insights Case Rep) - "The patient was managed by a multimodal approach, with lifestyle modification, pelvic floor strengthening exercises, pharmacologic management with bupropion sustained release 150 to 400 mg per day and topical lubricants, and psychosexual therapy as needed. The drug's impact on hormones and neurological pathways may contribute to decreased sexual desire, through the specific process is unknown. Adjuvant sexual education and therapy support has an imperative role in the plan of management in cases on going in the journey of reducing their weight and complaining of sexual performance affection."

Journal • Genetic Disorders • Hematological Disorders • Obesity • Sexual Disorders

Efficacy, Safety, and Tolerability of BRP-185 (Bupropion immediate-release (IR) and sustained-release (SR)) in Adults with Idiopathic Hypersomnia (ANZCTR) - P2 | N=120 | Not yet recruiting | Sponsor: Bioron Pharma

New P2 trial • Sleep Disorder

Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya (clinicaltrials.gov) - P4 | N=580 | Active, not recruiting | Sponsor: University of California, San Francisco | Recruiting ➔ Active, not recruiting

Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • Tobacco Cessation

A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder (clinicaltrials.gov) - P3 | N=388 | Recruiting | Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

New P3 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (clinicaltrials.gov) - P3 | N=180 | Active, not recruiting | Sponsor: Rose Research Center, LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Tobacco Cessation

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (clinicaltrials.gov) - P3 | N=180 | Recruiting | Sponsor: Rose Research Center, LLC | Active, not recruiting ➔ Recruiting | Trial completion date: Jun 2025 ➔ Sep 2025 | Trial primary completion date: Mar 2025 ➔ Jun 2025

Enrollment open • Trial completion date • Trial primary completion date • Tobacco Cessation

(KISV): Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment (clinicaltrials.gov) - P3 | N=500 | Recruiting | Sponsor: University of Kansas Medical Center | Trial completion date: Jul 2026 ➔ Mar 2027 | Trial primary completion date: Jan 2026 ➔ Sep 2026

Trial completion date • Trial primary completion date • Tobacco Cessation

Pharmacological treatment of antidepressant-induced sexual dysfunction in women: A systematic review and meta-analysis of randomized clinical trials. (PubMed, Clinics (Sao Paulo)) - "Bupropion SR 150 mg/b.i.d. is the most effective pharmacological treatment for AISD in women, though the evidence quality is low. Further clinical trials focusing on women with rigorous methodologies are needed to strengthen these findings."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Sexual Disorders

Cost-effectiveness analysis for implementation of smoking cessation strategies at primary health care settings in Tamil Nadu. (PubMed, PLoS One) - "Our study findings indicate that the need for healthcare providers and policymakers to implement PS3 with EC, NRT, Bupropion SR, as which was found to be cost-saving compared to current practices."

HEOR • Journal • Tobacco Cessation

Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya (clinicaltrials.gov) - P4 | N=580 | Recruiting | Sponsor: University of California, San Francisco | Trial completion date: Nov 2024 ➔ Sep 2025 | Trial primary completion date: Nov 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • Tobacco Cessation

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (clinicaltrials.gov) - P3 | N=180 | Active, not recruiting | Sponsor: Rose Research Center, LLC | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2024 ➔ Mar 2025

Enrollment closed • Trial primary completion date • Tobacco Cessation

Exposure to Bupropion-SR vs. Placebo is associated with reductions in smoking among persons receiving methadone with no stated interest in smoking cessation. (PubMed, Addict Behav) - "Data suggest that bupropion-SR significantly decreased the number of self-reported cigarettes smoked relative to placebo and reduced nicotine dependence severity by the end of the study. Follow-up studies are needed as these decreases were not identified throughout the full study period or at termination."

Journal • Addiction (Opioid and Alcohol) • Nicotine Addiction • Substance Abuse • Tobacco Cessation

Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: Medical University of Vienna

New P4 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

CPT-SMART for Treatment of PTSD and Cigarette Smoking (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: VA Office of Research and Development | Trial completion date: Sep 2024 ➔ Sep 2025 | Trial primary completion date: Sep 2024 ➔ Sep 2025

Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Drugs for COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tobacco Cessation

Sustained release of 3D printed bupropion hydrochloride tablets bearing Braille imprints for the visually impaired. (PubMed, Int J Pharm) - "In this study liquid crystal display (LCD) is introduced for the development of sustained release bupropion.HCl printed tablets. The selection of poly(ethylene glycol) (PEG)-diacrylate (PEGDA) of different molecular weights and the presence of surfactants or solubilizers disrupted the resin photopolymerization, thus controlling the BUP dissolution rates. A small batch scale-up study demonstrated the capacity of LCD to print rapidly a notable number of tablets within 24 min."

Journal

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (clinicaltrials.gov) - P3 | N=180 | Recruiting | Sponsor: Rose Research Center, LLC | Trial completion date: Jun 2024 ➔ Jun 2025 | Trial primary completion date: Feb 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Tobacco Cessation

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening (clinicaltrials.gov) - P=N/A | N=3228 | Active, not recruiting | Sponsor: Abramson Cancer Center at Penn Medicine | Recruiting ➔ Active, not recruiting

Enrollment closed • Lung Cancer • Oncology • Solid Tumor • Tobacco Cessation